Adherex Technologies Inc.

Adherex Technologies Inc.

October 27, 2005 08:00 ET

Adherex to Release Global Development Plans for Eniluracil on November 16 Conference Call

RESEARCH TRIANGLE PARK, NORTH CAROLINA--(CCNMatthews - Oct. 27, 2005) - Adherex Technologies Inc. (AMEX:ADH)(TSX:AHX), a biopharmaceutical company with a broad portfolio of oncology products under development, today announced that as part of its third quarter 2005 financial results conference call scheduled for November 16, 2005, the Company will release its global development plans for the oncology drug, eniluracil, which was in-licensed from GlaxoSmithKline (GSK) in July 2005. The presentation will include the new understanding of the drug's mechanism of action and the supporting scientific data that will enable the Company to initiate clinical trials this December and pivotal Phase III trials by mid-2007.

"Eniluracil represents an important and promising opportunity for Adherex, with a market potential we estimate in excess of a billion dollars," said William P. Peters, MD, PhD, MBA, Chairman and CEO. "When we announced the drug acquisition, we indicated that the details of the new mechanism and development plan would be released later in the year. In the past four months, we have made significant progress in defining the proper way to use this drug and in returning it to the clinic. On our November 16 call, we will present the reasons we believe the GSK Phase III trials failed, the way we plan to solve these issues, the data that support our understanding, how we plan to develop this drug rapidly and the global market potential for this drug."

Eniluracil blocks the breakdown of 5-FU, one of the most widely used cancer drugs in the world, and is being developed to increase 5-FU's effectiveness and reduce its toxicity. Although 5-FU is currently a mainstay of contemporary cancer treatment, it has therapeutic drawbacks, including severe skin, neural and other side effects, and variable pharmacology which affects its anti-tumor activity and safety profile. It also must be given intravenously. In combination with eniluracil, 5-FU can become orally active, with fewer side effects and more uniform and prolonged blood levels, and overcome tumor resistance, thereby improving its effectiveness.

Conference Call

Adherex will host a conference call at 10 a.m. ET on Wednesday, November 16, 2005 to discuss its third quarter 2005 financial results and announce the details for its eniluracil development program. This call will be webcast live via the Internet at

Live Participant Dial In (Toll Free, Canadian and US callers):
Live Participant Dial In (International): 719-457-2658
Conference Passcode: 9409555
Replay Number (Toll Free): 888-203-1112
Replay Number (International): 719-457-0820
Replay Passcode: 9409555

About Adherex Technologies

Adherex Technologies Inc. is a biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics. We aim to be a leader in developing innovative treatments that address important unmet medical needs in cancer. We currently have multiple products in the clinical stage of development, including ADH-1 (Exherin™), eniluracil and sodium thiosulfate (STS). ADH-1, our lead biotechnology compound, selectively targets N-cadherin, a protein present on certain tumor cells and established blood vessels that feed solid tumors. Eniluracil, an oral dihydropyrimidine dehydrogenase (DPD) inhibitor, was previously under development by GlaxoSmithKline for oncology indications. STS, a drug from our specialty pharmaceuticals pipeline, protects against the disabling hearing loss that can often result from treatment with platinum-based chemotherapy drugs. With a diversified portfolio of unique preclinical and clinical-stage cancer compounds and a management team with expertise in identifying, developing and commercializing novel cancer therapeutics, Adherex is emerging as a pioneering oncology company. For more information, please visit our website at

This press release contains forward-looking statements that involve significant risks and uncertainties. The actual results, performance or achievements of the Company might differ materially from the results, performance or achievements of the Company expressed or implied by such forward-looking statements. Such forward-looking statements include, without limitation, those regarding the development plans of the Company and the expected timing and results of such development. We can provide no assurance that such development will proceed as currently anticipated or that the expected timing or results of such development will be realized. We are subject to various risks, including those inherent in the biopharmaceutical industry, the early stage of our product candidates, the uncertainties of drug development, clinical trials and regulatory review, our reliance on collaborative partners, our need for additional capital to fund our operations, and our history of losses. For a more detailed discussion of related risk factors, please refer to our public filings available at and

Contact Information

  • Adherex Technologies Inc.
    Melissa Matson
    Director, Corporate Communications
    (919) 484-8484